Endocrine Abstracts

Familial non-medullary thyroid cancer (FNMTC) constitutes about 3–9% of all thyroid cancers. One of the genes believed to predispose to non-syndromic FNMTC is FOXE1. It contains a polyalanine tract (polyAla) with a variable number (11 – 22) of alanine residues. This length polymorphism could lead to changes in the FOXE1-encoded protein (FOXE1 transcription factor) structure and predispose to papillary thyroid cancer (PTC). The aim of the st...

Introduction: There are data reporting an increased risk of cardiovascular and metabolic complications in patients with NCAH. This is frequently attributed to glucocorticoid (over)use. It seems that long-term exposure to increased androgens concentration may also itself lead to diminished insulin sensitivity and increased risk of prediabetes and diabetes.Aim: The aim of the study was to assess the link between NCAH diagnosis and glucose metabolism distur...

Up to 5% of all pituitary tumors are hereditary (e.g. due to menin or AIP genes mutations). AIP gene mutations are more common in subjects with acromegaly, less than 30 years old at the onset of disease, and with FIPA family history. The study was aimed at the assessment of the frequency and characteristics of AIP-mutation related tumors in non-selected patients with pituitary macroadenomas.Material and Methods: The study included subsequent 131 patients...

Background: Double pituitary adenomas are a rare entity, which requires clinical attention and a careful follow-up.Case report: A 37-year-old man presented with left-sided painful gynecomastia. He denied typical symptoms of excessive growth hormone (GH) secretion and did not show any acromegalic features. Due to low testosterone and LH levels with mild hyperprolactinaemia, the patient was referred to pituitary MR, which revealed an 11 × 13 mm right-...

Cosyntropin stimulation test is the gold diagnostic standard used to test for NCAH. Genetic testing is not currently considered to be the primary diagnostic tool for NCAH. Still, it may be helpful in establishing a diagnosis if other results are unequivocal or for genetic counselling purposes. The study aimed at verifying the currently accepted threshold of 17-hydroxyprogesterone (17OHP) level (3 2.0 ng/ml) at which a cosyntropin stimulation test should be performed...